T.TramontinA
Las alternativas incluyen cambiar a otro GLP-1, optimizar la dosis, terapia combinada con otros medicamentos, intervenciones intensivas de estilo de vida o ciruga baritrica en casos seleccionados
The most difficult question to answer is what will be the target population of NAFLD/NASH pharmacologic treatment
Whether the anti-inflammatory and antioxidant advantages of GLP-1 RAs are direct results of GLP-1 receptor activation or indirect benefits mediated through better glycemic control, weight loss, and decreased visceral adiposity is a crucial topic raised by our data
Antibodies against agrin and LRP4, which are essential extracellular functional molecules in the MuSK signaling pathway, are therefore highly suspected to be associated with disease pathology, although their pathogenicities remain unknown (Rivner et al., 2020)
The following sgRNAs for GGT1 CRISPRi were used: sgGGT1 1 (HL-ID: 3) forward: 5-CACCGGTGCCTCCCACTGTCCGCCG-3